Two very recent clinical trials in drug-treatment naïve patients with melanoma BrM [ABC trial (Long et al., 2017) and CheckMate 204 trial (Tawbi et al., 2017)] reported a 46 and 52% intracranial response rate respectively following combined anti-PD-1 plus anti-CTLA-4 therapy. Here, CTLA4 is linked to melanoma.